Samsung Biologics' Third Quarter Sales Record High...Accumulated orders for this year are KRW 5.2435 trillion
Oct 28, 2025
|
According to the announcement on the 28th, consolidated sales in the third quarter of 2025 increased by 473.1 billion won year-on-year to 1.66 trillion won and operating profit increased by 390.2 billion won to 728.8 billion won.
On a separate basis, it recorded the largest quarterly sales ever thanks to the increase in sales contribution through the full operation of factories 1 to 4. Sales on a separate basis in the third quarter were KRW 1.2575 trillion and operating profit was KRW 633.4 billion, up KRW 1904 billion and KRW 188.9 billion from the same period last year, respectively.
Samsung Bioepis recorded 441 billion won in sales and 129 billion won in operating profit in the third quarter. Sales and operating profit increased by 110.7 billion won and 61.1 billion won, respectively, year-on-year, due to the expansion of biosimilar products in the global market due to the effect of launching new products in the U.S. this year.
Samsung Biologics predicted that it will achieve its upwardly revised annual sales growth guidance (25% to 30%) when announcing its second-quarter earnings on both a consolidated basis and a separate basis for Samsung Biologics.
Samsung Biologics' cumulative order amount based on this year's disclosure was 5.2435 trillion won, which was close to the annual order amount (5.4035 trillion won) of the previous year in 10 months. The commissioned development (CDO) business also secured eight new contracts, including global pharmaceutical companies, in the third quarter. Since its foundation, the cumulative orders have exceeded $20 billion, with 105 CMO and 154 CDO orders.
Samsung Biologics has secured 17 of the top 20 global pharmaceutical companies as customers. It has recently signed contracts with four of Japan's top 10 pharmaceutical and bio companies and is in final discussions with one of them, strengthening its order activities for the top 40 pharmaceutical companies worldwide.
It is also stepping up efforts to secure a super gap in production capacity. In April, the 180,000L plant, which increased operational efficiency through automation and digitalization, began operation and increased its total production capacity to 784,000L. By 2032, it plans to build three additional plants on the second bio-campus to increase its production capacity to a total of 1.324 million liters.
It is also continuing to invest in expanding its portfolio. In order to advance into the field of clinical trial trust (CRO), 'Samsung Organoids' service was introduced. It is also speeding up securing cutting-edge biotechnology such as antibodies and drug conjugates (ADC), multiple antibodies, and adenosine virus (AAV) to diversify product modality.
Based on thorough supply chain management and close collaboration with partners, Samsung Bioepis has steadily expanded sales of biosimilar products in the global market, showing solid earnings growth. In particular, SB17, an autoimmune disease treatment launched in the U.S. market in the first half of the year, has signed two private label contracts in which large private insurance companies distribute drugs under their own brand, accelerating their entry into the market by starting product supply in the third quarter. In July, it signed a U.S. partnership agreement with Harrow for the ophthalmic disease treatment Lucentis Biosimilar (SB11) and Eilea Biosimilar (SB15). In Korea, the company launched Prolia/Xgeva biosimilar (SB16), a treatment for bone disease, in July and August, respectively, and is expanding its product portfolio for various diseases, including increasing the number of products commercialized in Korea to a total of 11.
Reporter Kim So-hyung compact@sportschosun.com
This article was translated by Naver AI translator.
